comparemela.com

Latest Breaking News On - Institutional investors weigh in on centessa pharmaceuticals - Page 2 : comparemela.com

Brokerages Set Centessa Pharmaceuticals plc (NASDAQ:CNTA) Price Target at $9.43

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) have earned an average rating of “Moderate Buy” from the eight brokerages that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month […]

Harris-rotman
Centessa-pharmaceuticals-stock-performance
Goldman-sachs-group
Centessa-pharmaceuticals
Morgan-stanley
Sio-capital-management
Institutional-investors-weigh-in-on-centessa-pharmaceuticals
News-ratings-for-centessa-pharmaceuticals-daily
Nasdaq
Affinity-asset-advisors
Analyst-recommendations-for-centessa-pharmaceuticals
Platinum-investment-management-ltd

Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Up 5%

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) shot up 5% on Monday . The stock traded as high as $6.52 and last traded at $6.52. 22,752 shares were traded during trading, a decline of 85% from the average session volume of 155,269 shares. The stock had previously closed at $6.21. Analysts Set […]

Harris-rotman
Susquehanna-international-group
Securities-exchange-commission
Centessa-pharmaceuticals-company-profile
Goldman-sachs-group-inc
Jpmorgan-chase-co
Nasdaq
Barclays-plc
Centessa-pharmaceuticals-stock
Centessa-pharmaceuticals
Institutional-investors-weigh-in-on-centessa-pharmaceuticals
Morgan-stanley

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $9.17 Average Price Target from Analysts

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 […]

Harris-rotman
Analyst-recommendations-for-centessa-pharmaceuticals
Centessa-pharmaceuticals
Centessa-pharmaceuticals-company-profile
Securities-exchange-commission
News-ratings-for-centessa-pharmaceuticals-daily
Institutional-investors-weigh-in-on-centessa-pharmaceuticals
Morgan-stanley
Goldman-sachs-group
Nasdaq
Centessa-pharmaceuticals-stock-performance
Affinity-asset-advisors

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Short Interest Down 29.7% in August

Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) saw a large drop in short interest in the month of August. As of August 31st, there was short interest totalling 1,300,000 shares, a drop of 29.7% from the August 15th total of 1,850,000 shares. Approximately 2.3% of the shares of the company are sold short. Based […]

Centessa-pharmaceuticals-price-performance
Institutional-investors-weigh-in-on-centessa-pharmaceuticals
Nasdaq
News-ratings-for-centessa-pharmaceuticals-daily
Barclays-plc
Centessa-pharmaceuticals
Goldman-sachs-group
Susquehanna-international-group
Renaissance-technologies
Goldman-sachs-group-inc
Jpmorgan-chase-co

Centessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 8.4%

Centessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 8.4%
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Tial-bush
Antoine-yver
Jpmorgan-chase-co
Institutional-investors-weigh-in-on-centessa-pharmaceuticals
News-ratings-for-centessa-pharmaceuticals-daily
Securities-exchange-commission
Prelude-capital-management
Barclays-plc
Centessa-pharmaceuticals
Susquehanna-international-group
Nasdaq
Renaissance-technologies
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.